Omeros (OMER) Insider Rajiv Shah Buys 15,000 Shares

On June 18, 2026, Rajiv Shah purchased 15,000 shares of Omeros Corporation (NasdaqGM: OMER). This insider buying activity did not specify a purchase price, but it indicates a notable interest in the company, which traded near $10.28 on Monday.

Insider Buying and Selling at Omeros Corporation

Several insiders, including Rajiv Shah, acquired 15,000 shares each of Omeros Corporation on June 18, 2026. Other insiders who participated in this buying spree include Leroy Hood, Diana Perkinson, Thomas Bumol, Arnold Hanish, and Peter Demopulos, MD. None of these transactions were part of a pre-planned trading scheme.

Other Institutional Activity in Omeros Corporation

BlackRock, Inc. increased its holdings in Omeros Corporation by 247,188 shares, bringing its total to approximately 5.31 million shares valued at $56.1 million. Ingalls & Snyder LLC added 110,724 shares, totaling about 3.56 million shares worth $37.6 million. Vanguard Capital Management LLC opened a new position with 2.98 million shares valued at $31.5 million. UBS Group AG grew its stake by 117,749 shares to hold 2.34 million shares worth $24.7 million. State Street Corp raised its position by 346,049 shares, ending with 1.92 million shares valued at $20.3 million.

Omeros Corporation Stock Down 44.0%

Shares of Omeros Corporation, listed on the NasdaqGM under the ticker OMER, traded around $10.28 on Monday. The company has a market capitalization of approximately $744 million and a P/E ratio of 9.02. Its beta is 2.526, indicating higher volatility compared to the market. The stock has seen a 52-week low of $2.95 and a high of $17.65, with a 50-day moving average of $12.22 and a 200-day moving average of $10.11.

Analysts Set New Price Targets

On April 21, 2026, D. Boral Capital maintained its 'buy' rating for Omeros Corporation with a price target of $36.0. HC Wainwright & Co. also maintained a 'buy' rating, setting a target of $40.0 as of January 8, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $40.0 based on one analyst opinion.

About Omeros Corporation

Omeros Corporation is a Seattle-based biopharmaceutical company focused on discovering and developing small-molecule and protein therapeutics for immunologic diseases. Led by CEO Dr. Gregory A. Demopulos, the company employs about 175 people. Omeros' lead product candidate, Narsoplimab, is in clinical trials for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy and other conditions. The company also has several other products in various stages of clinical and preclinical development.

Bottom Line

Rajiv Shah's recent purchase of Omeros Corporation shares highlights insider confidence in the company's potential. As a clinical-stage biopharmaceutical firm, Omeros is actively developing treatments for significant health conditions. Investors often track insider transactions like these as they can signal insider sentiment about the company's future. However, it's important to remember that such trades are disclosed after the fact and may not reflect current positions.